comparemela.com

Latest Breaking News On - Oncology clinical development - Page 7 : comparemela.com

Datopotamab Deruxtecan Combo Shows Promise in Advanced Lung Cancer Trial

Datopotamab Deruxtecan Combo Shows Promise in Advanced Lung Cancer Trial
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Japan
Tokyo
United-states
American
Daiichi-sankyo
Mark-rutstein
Cristian-massacesi
Division-of-internal-medicine
Merck-co-inc
American-society-of-clinical-oncology
Astrazeneca
National-cancer-center-hospital

Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial

In previously untreated patients, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy demonstrated objective response rates of 57%. | June 5, 2023

United-states
Japan
Sapporo
Hokkaido
Tokyo
American
Mark-rutstein
Ann-onc
Cristian-massacesi
Daiichi-sankyo
Astrazeneca
Sarah-cannon-research-institute

Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial

In previously untreated patients, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy demonstrated objective response rates of 57%. | June 9, 2023

Tokyo
Japan
Cambridge
Cambridgeshire
United-kingdom
United-states
Sapporo
Hokkaido
American
Mark-rutstein
Ann-onc
Cristian-massacesi

FDA Extends Review Period for Quizartinib for Adults With FLT3-ITD-Positive AML

Daiichi Sankyo announced that the new deadline for review of the application is July 24, 2023.

United-states
American
Daiichi-sankyo
Mark-rutstein
Mikkael-sekeres
University-of-miami-health-system
American-cancer-society
European-hematology-association-congress
Oncology-clinical-development
Prescription-drug-user-fee-act
Risk-evaluation
Mitigation-strategies

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
United-states
Texas
Tokyo
America
American
Koji-ogiwara
Daiichi-sankyo
Mark-rutstein
Jennifer-brennan
Daiichi-sankyo-inc
Drug-administration

vimarsana © 2020. All Rights Reserved.